Leap Therapeutics, Inc. announced the Company will be presenting updated data from Part B of the DisTinGuish Study evaluating DKN-01 in combination with tislelizumab, BeiGene's anti-PD-1 antibody, in second-line gastroesophageal junction/gastric (GEJ/G) cancer patients whose tumors express high levels of DKK1 (DKK1-high) at the Society of Immunotherapy for Cancer (SITC) 37th Annual Meeting being held in Boston, MA on November 8-12, 2022. Leap will also present preclinical DKN-01 data supporting the DeFianCe Study, a Phase 2 study of DKN-01 in combination with bevacizumab and standard of care chemotherapy in patients with advanced colorectal cancer who have received one prior systemic therapy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.43 USD | +2.97% | +2.10% | -41.38% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.38% | 92.98M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.76% | 21.96B | |
-8.70% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- LPTX Stock
- News Leap Therapeutics, Inc.
- Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting